Annexon (ANNX) Research & Development (2019 - 2026)
Annexon's (ANNX) quarterly Research & Development came in at $35.8 million in Q1 2026, down 25.72% year-on-year from $48.2 million in Q1 2025, and down 16.11% quarter-over-quarter from $42.7 million in Q4 2025.
Annexon (ANNX) Research & Development (2019 - 2026) Analysis & Trends
Annexon's Research & Development history runs 8 years deep, the most recent figure standing at $35.8 million for Q1 2026.
- On a quarterly basis, Research & Development fell 25.72% year-over-year to $35.8 million in Q1 2026; TTM through Mar 2026 was $172.3 million, a 17.48% increase from a year earlier, with the FY2025 full-year figure at $184.7 million, up 54.63% from the prior year.
- Research & Development eased to $35.8 million in Q1 2026 per ANNX's latest filing, from $42.7 million in the prior quarter.
- Across five years, Research & Development topped out at $49.7 million in Q3 2025 and bottomed at $21.0 million in Q1 2024.
- The 5-year median for Research & Development is $30.1 million (2024), against an average of $33.3 million.
- Across the five-year window, Research & Development sank 35.19% in 2024 and soared 129.83% in 2025, its largest moves.
- Year by year, Research & Development stood at $28.5 million in 2022, then dropped by 18.46% to $23.3 million in 2023, then surged by 86.33% to $43.4 million in 2024, then declined by 1.6% to $42.7 million in 2025, then decreased by 16.11% to $35.8 million in 2026.
- Per Business Quant, the three latest ANNX Research & Development figures stand at $35.8 million (Q1 2026), $42.7 million (Q4 2025), and $49.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 1.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 541.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | -443.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 343.97 Mn |
| 10 | Annexon | 1.02 Bn | 798.41 Mn | - | 35.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35.79 Mn |
| Dec 31, 2025 | 42.66 Mn |
| Sep 30, 2025 | 49.70 Mn |
| Jun 30, 2025 | 44.16 Mn |
| Mar 31, 2025 | 48.18 Mn |
| Dec 31, 2024 | 43.35 Mn |
| Sep 30, 2024 | 30.11 Mn |
| Jun 30, 2024 | 25.03 Mn |
| Mar 31, 2024 | 20.96 Mn |
| Dec 31, 2023 | 23.27 Mn |
| Sep 30, 2023 | 27.89 Mn |
| Jun 30, 2023 | 30.25 Mn |
| Mar 31, 2023 | 32.35 Mn |
| Dec 31, 2022 | 28.54 Mn |
| Sep 30, 2022 | 27.86 Mn |
| Jun 30, 2022 | 29.11 Mn |
| Mar 31, 2022 | 27.00 Mn |
| Dec 31, 2021 | 27.22 Mn |
| Sep 30, 2021 | 27.58 Mn |
| Jun 30, 2021 | 24.57 Mn |